loading . . . Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial Across all doses, VAX-31 was well tolerated, had a safety profile similar to PCV20, and elicited robust OPA responses across all 31 serotypes. These data further validate the potential for VAX-31 to⦠https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00059-9/abstract?CampaignID=987&interactionId=uRLoZyiyaU-S40uOkorkMFpbZbW929HaFekPN22hIZIhcLYHDGu5zQ%3D%3D